Trial Profile
A Phase II Study of Temozolomide (TMZ) Following Stereotactic Radiosurgery (SRS) for Patients With Newly Diagnosed Brain Metastases.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2012
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Brain metastases
- Focus Therapeutic Use
- 19 Sep 2011 Planned end date changed from Mar 2012 to Jun 2011 as reported by ClinicalTrials.gov.
- 01 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Sep 2008 Planned end date changed from Feb 2012 to Mar 2012 as reported by ClinicalTrials.gov.